# Trial of INI-4001 in Patients With Advanced Solid Tumours

> **NCT06302426** · PHASE1 · RECRUITING · sponsor: **Inimmune Corporation** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** INI-4001
- **COMBINATION_PRODUCT:** Nivolumab
- **COMBINATION_PRODUCT:** Pembrolizumab
- **COMBINATION_PRODUCT:** Cemiplimab
- **COMBINATION_PRODUCT:** Avelumab
- **COMBINATION_PRODUCT:** Atezolizumab
- **COMBINATION_PRODUCT:** Durvalumab

## Key facts

- **NCT ID:** NCT06302426
- **Lead sponsor:** Inimmune Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- Avance Clinical Pty Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06302426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06302426, "Trial of INI-4001 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06302426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*